Introduction to Risk Stratification in Gastric Metaplasia

Gastric intestinal metaplasia (GIM) serves as a critical precursor to gastric adenocarcinoma. Consequently, accurately identifying patients at high risk for progression remains a top clinical priority. A recent prospective study validates the EGGIM gastric cancer risk assessment tool and introduces an innovative modified model. This updated approach incorporates microvascular (MV) pattern abnormalities to enhance diagnostic precision significantly. Furthermore, researchers evaluated 144 patients using both standard endoscopic grading and targeted microvascular pattern assessments.

During the study, clinicians compared endoscopic findings against the operative link on gastric intestinal metaplasia assessment (OLGIM). This histological framework remains the gold standard for staging. Specifically, the EGGIM system scores five gastric regions to estimate the total extent of metaplasia. By providing a real-time endoscopic score, this tool helps doctors decide which patients require intensive surveillance and which may avoid unnecessary biopsies.

Enhancing EGGIM Gastric Cancer Risk Assessment with Microvascular Analysis

The study demonstrated that the standard EGGIM score effectively identifies high-risk OLGIM III-IV stages. Specifically, using a cutoff value of ≥4, the tool achieved a sensitivity of 90.90% and a specificity of 73%. However, the researchers discovered that altered microvascular patterns serve as a significant independent risk factor. Additionally, by integrating these MV abnormalities into a modified model, the diagnostic performance improved remarkably.

The area under the curve (AUC) rose from 0.885 in the standard EGGIM to 0.941 in the modified version. Therefore, combining morphological grading with microvascular analysis allows for more reliable risk stratification in clinical practice. This approach could potentially reduce the reliance on random biopsies while ensuring high-risk patients receive the necessary longitudinal care. Similarly, clinicians can utilize these advanced endoscopic techniques to optimize gastric cancer screening protocols.

Frequently Asked Questions

What is the EGGIM scoring system?

The Endoscopic Grading of Gastric Intestinal Metaplasia (EGGIM) is a scoring system (0–10) that evaluates five areas of the stomach. It uses high-definition endoscopy to estimate the percentage of mucosa affected by metaplasia in each region.

How do microvascular patterns improve gastric cancer risk assessment?

Abnormal microvascular (MV) patterns are indicators of neoplastic transformation. Adding MV evaluation to the standard EGGIM score increases diagnostic accuracy (AUC 0.941), helping to better identify patients at the highest risk of developing gastric cancer.

Is EGGIM intended to replace histological biopsies?

While EGGIM shows high concordance with OLGIM stages, it currently serves as a tool to guide targeted biopsies and stratify surveillance needs. It aims to reduce unnecessary random biopsies while ensuring that high-risk areas are not missed.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Refer to the latest local and national guidelines for clinical practice.

References

Zhang X et al. Endoscopic grading of gastric intestinal metaplasia and microvascular pattern for assessing gastric cancer risk: a prospective study. Ann Med. 2026 Dec undefined. doi: 10.1080/07853890.2026.2668887. PMID: 42107110.

Pimentel-Nunes P, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy. 2019;51(4):365-388.

Esposito G, et al. Endoscopic grading of gastric intestinal metaplasia (EGGIM): a multicenter validation study. Endoscopy. 2019;51(6):515-521.